Diatrizoate Meglumine: uses, dosing, side effects & brands
Diatrizoate Meglumine is a medicine sold in the U.S. under 3 brand and generic names. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Available as
- Injectable · Solution
- Sold as
- 3 products — Cardiografin, Hypaque and Hypaque-Cysto
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
Every diatrizoate meglumine product we track (3)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|
| 1 | Not yet rated | Prescription | Injectable | No data | — | View → | |
| 2 | Not yet rated | Prescription | Injectable | No data | — | View → | |
| 3 | Not yet rated | Prescription | Solution | No data | — | View → |
Combination products containing diatrizoate meglumine
A combination is a different drug — different dosing, different warnings. It is listed here so you can find it, not so you can substitute it.
How long diatrizoate meglumine keeps
No diatrizoate meglumine label we read sets a separate limit for after opening, but they do specify how it must be stored — and the stability behind any date assumes those conditions.
What people report to the FDA about diatrizoate meglumine
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 183 reports naming diatrizoate meglumine, and the FDA flagged 95% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- dyspnoea72 reports
- nausea72 reports
- rash69 reports
- confusional state66 reports
- pericarditis64 reports
- psoriatic arthropathy64 reports
- treatment failure64 reports
- type 2 diabetes mellitus64 reports
Read these as a signal, not a rate. A report does not mean diatrizoate meglumine caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 25, 2026.
Related calculators
Frequently asked questions
Can you take diatrizoate meglumine with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run diatrizoate meglumine against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What brand names is diatrizoate meglumine sold under?
We track 3 diatrizoate meglumine-containing products in the U.S.: Cardiografin, Hypaque and Hypaque-Cysto. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.
What forms does diatrizoate meglumine come in?
Across the brands we track, diatrizoate meglumine is currently marketed as injectable and solution, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic diatrizoate meglumine?
We do not currently list a generic-labelled diatrizoate meglumine product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Diatrizoate Meglumine: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/diatrizoate-meglumine
- MLA
- “Diatrizoate Meglumine: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/diatrizoate-meglumine.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for diatrizoate meglumine on DailyMed (NIH) ↗.